NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

FDA Approves CARDAMYST: First Self-Administered Nasal Spray for PSVT

Milestone's (MIST) CARDAMYST nasal spray is FDA-approved for adults with PSVT (fast heart rate episodes). It's the first quick, self-administered home treatment.

FDA Approves CARDAMYST: First Self-Administered Nasal Spray for PSVT
Credit: Milestone Pharmaceuticals
Already have an account? Sign in.
12/15/2025 · 5:50 AM
MIST
/ Don’t stop at just one post.

Related↓

Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
04/10/2026 · 7:14 AM

Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)

Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.

/ Subscriber only
/ Read more

Feed↓

Bed Bath & Beyond Beats Q1 Estimates with First Revenue Growth in 19 Quarters
04/27/2026 · 5:02 PM

Bed Bath & Beyond Beats Q1 Estimates with First Revenue Growth in 19 Quarters

Bed Bath & Beyond beat forecasts, cut costs, improved sales, and is shifting from survival to growth with a leaner business model.

/ Subscriber only
Catalyst Pharmaceuticals Stock Surges on Angelini Pharma Buyout Rumors
Featured/ 04/27/2026 · 4:31 PM

Catalyst Pharmaceuticals Stock Surges on Angelini Pharma Buyout Rumors

Angelini Pharma may buy Catalyst Pharmaceuticals. Talks are early, but news pushed Catalyst’s stock up. No deal is certain yet.

/ Subscriber only
Starboard Value Takes Big Stake in Flowserve and Pushes for Higher Profits
04/27/2026 · 3:31 PM

Starboard Value Takes Big Stake in Flowserve and Pushes for Higher Profits

Starboard buys big stake in Flowserve, pushes for higher profits as AI boosts power demand; stock rises on growth hopes.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe